NO871229L - Farmasoeytisk blanding som inneholder oksazepam. - Google Patents

Farmasoeytisk blanding som inneholder oksazepam. Download PDF

Info

Publication number: NO871229L
Authority: NO; Norway
Prior art keywords: dihydro; chloro; hydroxy; phenyl; benzodiazepine
Prior art date: 1985-07-24

Application number

NO87871229A

Other languages

English (en)

Norwegian (no)

Other versions

NO871229D0 (no

Inventor

Pawan Seth

Original Assignee

Pyare Seth

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-07-24

Filing date

1987-03-24

Publication date

1987-03-24

1987-03-24 Application filed by Pyare Seth filed Critical Pyare Seth

1987-03-24 Publication of NO871229D0 publication Critical patent/NO871229D0/no

1987-03-24 Publication of NO871229L publication Critical patent/NO871229L/no

Links

239000000203 mixture Substances 0.000 title claims description 38
ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 77
239000003937 drug carrier Substances 0.000 claims description 20
239000000546 pharmaceutical excipient Substances 0.000 claims description 18
208000019116 sleep disease Diseases 0.000 claims description 15
238000000034 method Methods 0.000 claims description 14
239000013543 active substance Substances 0.000 claims description 13
239000002245 particle Substances 0.000 claims description 12
229920002472 Starch Polymers 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 10
239000000932 sedative agent Substances 0.000 claims description 10
230000001624 sedative effect Effects 0.000 claims description 10
239000002904 solvent Substances 0.000 claims description 10
238000004090 dissolution Methods 0.000 claims description 9
239000010419 fine particle Substances 0.000 claims description 9
235000019698 starch Nutrition 0.000 claims description 9
239000008107 starch Substances 0.000 claims description 9
239000003960 organic solvent Substances 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 7
239000004094 surface-active agent Substances 0.000 claims description 7
239000008024 pharmaceutical diluent Substances 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 5
208000019901 Anxiety disease Diseases 0.000 claims description 4
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
239000002202 Polyethylene glycol Substances 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims description 4
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
239000008108 microcrystalline cellulose Substances 0.000 claims description 4
229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 4
229920001223 polyethylene glycol Polymers 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
238000001179 sorption measurement Methods 0.000 claims description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 3
239000001593 sorbitan monooleate Substances 0.000 claims description 3
235000011069 sorbitan monooleate Nutrition 0.000 claims description 3
229940035049 sorbitan monooleate Drugs 0.000 claims description 3
230000036506 anxiety Effects 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
229960004535 oxazepam Drugs 0.000 description 28
239000003826 tablet Substances 0.000 description 24
239000008280 blood Substances 0.000 description 13
210000004369 blood Anatomy 0.000 description 13
230000000694 effects Effects 0.000 description 13
239000003814 drug Substances 0.000 description 11
229940079593 drug Drugs 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
238000009472 formulation Methods 0.000 description 8
230000000147 hypnotic effect Effects 0.000 description 8
239000004615 ingredient Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
150000001875 compounds Chemical class 0.000 description 6
238000003756 stirring Methods 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
229940049706 benzodiazepine Drugs 0.000 description 2
150000001557 benzodiazepines Chemical class 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
239000012059 conventional drug carrier Substances 0.000 description 2
GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
229910052901 montmorillonite Inorganic materials 0.000 description 2
238000000465 moulding Methods 0.000 description 2
239000006187 pill Substances 0.000 description 2
208000022925 sleep disturbance Diseases 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000002156 adsorbate Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000000049 anti-anxiety effect Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000002567 autonomic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
235000019821 dicalcium diphosphate Nutrition 0.000 description 1
229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
230000005264 electron capture Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000005661 hydrophobic surface Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
235000009973 maize Nutrition 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
238000010951 particle size reduction Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
-1 polyhydroxyethylene stearate Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000002618 waking effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO87871229A 1985-07-24 1987-03-24 Farmasoeytisk blanding som inneholder oksazepam. NO871229L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP1985/000408 WO1987000428A1 (en)	1985-07-24	1985-07-24	Oxazepam containing pharmaceutical composition

Publications (2)

Publication Number	Publication Date
NO871229D0 NO871229D0 (no)	1987-03-24
NO871229L true NO871229L (no)	1987-03-24

Family

ID=8165057

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO87871229A NO871229L (no)	1985-07-24	1987-03-24	Farmasoeytisk blanding som inneholder oksazepam.

Country Status (4)

Country	Link
EP (1)	EP0232254A1 (da)
DK (1)	DK149787D0 (da)
NO (1)	NO871229L (da)
WO (1)	WO1987000428A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH673947A5 (da) *	1986-09-23	1990-04-30	Sandoz Ag
SE8803935L (sv) *	1988-10-31	1990-05-01	Kabivitrum Ab	Laekemedelskomposition
US6531158B1 (en)	2000-08-09	2003-03-11	Impax Laboratories, Inc.	Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
EP4729048A1 (en) *	2024-10-15	2026-04-22	Neuraxpharm Pharmaceuticals, S.L.	Orally dispersible tablets of oxazepam

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1349158A (en) *	1971-11-19	1974-03-27	Arpic Sa	Pharmaceutical compositions
DE2400819C2 (de) *	1974-01-09	1982-04-22	Bayer Ag, 5090 Leverkusen	Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung

1985
- 1985-07-24 WO PCT/EP1985/000408 patent/WO1987000428A1/en not_active Ceased
- 1985-07-24 EP EP85903997A patent/EP0232254A1/en not_active Withdrawn
1987
- 1987-03-24 DK DK149787A patent/DK149787D0/da not_active IP Right Cessation
- 1987-03-24 NO NO87871229A patent/NO871229L/no unknown

Also Published As

Publication number	Publication date
DK149787A (da)	1987-03-24
NO871229D0 (no)	1987-03-24
WO1987000428A1 (en)	1987-01-29
DK149787D0 (da)	1987-03-24
EP0232254A1 (en)	1987-08-19

Publication	Publication Date	Title
US3488418A (en)	1970-01-06	Sustained relief analgesic composition
US5958979A (en)	1999-09-28	Stabilized medicaments containing thyroid hormones
US4900558A (en)	1990-02-13	Sustained release ibuprofen formulation including a core of ibuprofen and a microcrystalline cellulose and a covering of acrylic polymer and hydroxylated cellulose derivative
AU676315B2 (en)	1997-03-06	Stabilized solid pharmaceutical preparation and method of producing the same
JP2002529407A (ja)	2002-09-10	Ｌ−ｄｏｐａエチルエステル含有分散性組成物
NO863254L (no)	1987-02-16	Sammensetning for fremstilling av stabile natriumaspirintabletter.
US3524910A (en)	1970-08-18	Sustained relief analgesic compositions
CN101522185B (zh)	2012-07-11	抗抑郁剂
EP0351353A1 (en)	1990-01-17	Anti-inflammatory pharmaceutical composition with an ibuprofen base, with elimination, in solution, of the bitter taste, burning in the throat and intestinal toxicity
HU224983B1 (en)	2006-05-29	Swallow tablet comprising paracetamol
CZ177397A3 (en)	1997-11-12	Use of frank incense for preparing a medicament for prophylactic and therapeutic treatment of alzheimer's disease
US3428728A (en)	1969-02-18	Timed release sublingual medications
US4619936A (en)	1986-10-28	Pharmaceutical compositions having appetite reducing activity and a process for their preparation
JP6062705B2 (ja)	2017-01-18	医薬組成物
NO822385L (no)	1983-01-14	Terapeutisk preparat.
JP2001503734A (ja)	2001-03-21	カリウム、ナトリウムおよびトリスオキサプロジン塩医薬組成物
WO2011140981A1 (zh)	2011-11-17	5'-甲氧基-3'，4'-次甲二氧基桂皮酸异丁基酰胺在制备抗抑郁药物中的应用
JP2007131561A (ja)	2007-05-31	経口固形製剤及びその製造法
GB2577363A (en)	2020-03-25	Liquid pharmaceutical composition for oral administration comprising paracetamol and codeine phosphate
US20020040051A1 (en)	2002-04-04	Solid dispersion of ipriflavone for oral administration and its manufacturing methods
WO1987000428A1 (en)	1987-01-29	Oxazepam containing pharmaceutical composition
EP2481395A1 (en)	2012-08-01	Sachet, effervescent tablet and dry syrup of otilonium
US4493827A (en)	1985-01-15	Method of inducing sleep
JP4710240B2 (ja)	2011-06-29	医薬組成物
CN120022238B (zh)	2025-09-05	含司来帕格的混悬剂及其制备方法